Dr. Alvira Macanovic reports

VENTRIPOINT TO HOLD ANNUAL GENERAL MEETING OF SHAREHOLDERS ON NOVEMBER 1, 2023

Ventripoint Diagnostics Ltd. will hold its annual general and special meeting of shareholders on Wednesday, Nov. 1, 2023, at 11 a.m. ET in a virtual-only format conducted via gotomeeting for the following purposes:

1. To receive the audited financial statements of the corporation;
2. To appoint an auditor for the corporation;
3. To elect each of the directors of the corporation;
4. To reapprove and ratify the corporation's incentive stock option plan.

Following the AGM, president and chief executive officer, Dr. Alvira Macanovic, will provide a corporate update.

Call in details for the virtual-only AGM are as displayed herein.

In order to dial into the meeting within Canada, shareholders and observers will phone 1-647-497-9391 and enter the access code noted herein.

Outside of Canada, please find your local number:

United States:   1-646-749-3129

France:  33-430-001-234

Germany:  49-721-9881-4161

Ireland:   353-16-572-651

Netherlands:  31-207-941-377

Spain:   34-912-71-8491

Sweden:   46-853-527-836

Switzerland:   41-435-5015-61

United Kingdom:  44-330-221-0088

Access code for dial-in:  923-830-821

Shareholders and observers may also join the meeting by computer, tablet or smartphone by downloading the application on-line and, once the application is loaded, opening a link (as shown in the original version of this release) for the meeting.

The notice and management information circular and form of proxy for the AGM are available on the corporation's website and under the corporations profile at SEDAR+. The board has fixed Sept. 25, 2023, as the record date for determining the shareholders entitled to receive notice of the annual general meeting or any adjournment or postponement thereof. Holders of record of the company's ordinary shares at the close of business on the record date are entitled to attend the annual general meeting and any adjournment or postponement thereof in person.

Ventripoint's financial information is available on the corporation's website.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.